Not Logged In

Opthea Limited, formerly Circadian Technologies Limited, is engaged in developing and commercializing therapies primarily for eye diseases. The Company operates in medical technology and healthcare industry in Australia. The Company is involved in the development activities, which are based on the intellectual property portfolio covering key targets, such as vascular endothelial growth factors [VEGF]-C, -D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, including angiogenesis and lymph angiogenesis respectively, as well as vascular leakage. It is developing its lead molecule, which is a soluble form of VEGFR-3 referred to as OPT-302, for the treatment of wet age-related macular degeneration (wet AMD). OPT-302 blocks two members of the vascular endothelial growth factor family, VEGF-C and VEGF-D, which cause blood vessels to grow and leak. It is investigating OPT-302 in an ongoing Phase I/IIA clinical trial in wet AMD patients.